المؤلفون: Zhao HY; From the Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China (H-YZ, YH, LZ); Department of Internal Medicine, Cancer Hospital of Ha'erbin Medical University, Haerbin, Heilongjiang, China (G-YC, X-LL); Department of Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China (J-FF, M-QS); Department of Oncology, Jilin Cancer Hospital, Changchun, Jilin, China (YC, L-XM); Chemotherapy Center, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China (Y-PZ, C-PG); and Department Chemotherapy, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China (X-QS, DZ)., Chen GY, Huang Y, Li XL, Feng JF, Shi MQ, Cheng Y, Ma LX, Zhang YP, Gu CP, Song XQ, Zhou D, Zhang L

المصدر: Medicine [Medicine (Baltimore)] 2015 Jan; Vol. 94 (2), pp. e249.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE

مواضيع طبية MeSH: Quinazolines*/administration & dosage , Quinazolines*/adverse effects, Adenocarcinoma/*drug therapy , Deoxycytidine/*analogs & derivatives , Fluorouracil/*analogs & derivatives , Genes, erbB-1/*genetics , Lung Neoplasms/*drug therapy, Adenocarcinoma/genetics ; Adenocarcinoma/metabolism ; Adenocarcinoma/pathology ; Adenocarcinoma of Lung ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Biomarkers ; Capecitabine ; China ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Disease-Free Survival ; Drug Synergism ; Drug Therapy, Combination ; Erlotinib Hydrochloride ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Genes, ras/genetics ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Male ; Mutation ; Neoplasm Staging ; Thymidine Phosphorylase/metabolism ; Treatment Outcome